Piramal Pharma Limited (PPL) offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 15 global facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organisation (CDMO), Piramal Critical Care (PCC), a Complex Hospital Generics business, and the India Consumer Healthcare business selling over-the-counter products.
PPS offers end-to-end development and manufacturing solutions through a globally integrated network of facilities across the drug life cycle to innovators and generic companies. PCC’s complex hospital product portfolio includes inhalation anaesthetics, intrathecal therapies for spasticity and pain management, injectable pain and anaesthetics, injectable anti-infectives, and other therapies. The India Consumer Healthcare business is among the leading players in India in the self-care space, with established brands in the India consumer healthcare market. In addition, PPL has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market. In October 2020, the company received a growth equity investment from the Carlyle Group.
As a trusted partner, Piramal Pharma Solutions, one of the largest manufacturing companies in the world, aims to reduce the burden of disease by enhancing value for pharmaceutical companies.Read More
A leading producer of Inhaled Anesthetics and a global player in Hospital Generics, Piramal Critical Care is committed to saving lives by delivering critical care solutions for patients and healthcare providers across the globe.Read More
Consumer Products Division (CPD), Piramal's Domestic Healthcare business division, caters to the Indian self-care market with its purpose to improve people's lives by addressing their routine-disruptorsRead More
Allergan India Private Limited, a joint venture between Allergan (now part of AbbVie) and Piramal Pharma Limited, commenced commercial operations in 1996.Read More